Search This Blog

Tuesday, January 21, 2020

Trovagene up 30% ahead of onvansertib data presentation

Nano cap Trovagene (TROV +29.7%) is up on modestly higher volume ahead of a presentation of Phase 1b/2 data on lead candidate onvansertib in KRAS-positive colorectal cancer at the ASCO GI Cancers Symposium this Saturday, January 25.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)